Clinical trials
Leukemia Acute Myeloid - AML clinical trials
Below are recruiting leukemia acute myeloid - aml clinical trials, each written for real people, not researchers. We’re tracking 100 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06608732RecruitingPhase 2
CAR-T therapy plus stem cell transplant for B-cell ALL with MRD
This trial tests a combination of a CAR-T cell therapy (Inaticabtagene Autoleucel) followed by your own stem cells being transplanted back into you. It is for teenagers and adults who have B-cell acute lymphoblastic leukemia (ALL) that is in first complete remission but still has tiny amounts of cancer cells (called MRD) that can be detected by sensitive tests.
Tianjin, Tianjin MunicipalityAges 16–70 - NCT06561074RecruitingPhase 2
Study of calaspargase, decitabine, and venetoclax for young T-cell cancer
This trial tests a combination of three drugs (calaspargase, decitabine, and venetoclax) for children, teens, and young adults with T-cell leukemia or lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help destroy cancer cells.
Houston, TexasAges 1 month–21 years - NCT07003737Recruiting
Blinatumomab before stem cell transplant for high-risk B-ALL
This trial tests giving a drug called blinatumomab before a stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) that is in remission and has no detectable cancer cells. The goal is to see if this extra treatment helps prevent the leukemia from coming back after transplant.
Hangzhou, ZhejiangAges 18–65 - NCT05645718RecruitingPhase 2
Chemo plus targeted antibodies for relapsed childhood B-ALL
This Phase 2 study tests a combination treatment for children, teens, or young adults whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or did not respond to initial therapy. It may help patients who cannot safely receive certain standard medicines like anthracyclines or who cannot tolerate PEG-asparaginase.
Houston, TexasAges 1–25 - NCT07155226RecruitingPhase 1/Phase 2
Study of AZD3632 for advanced blood cancers with certain gene changes
This trial is testing a new drug, AZD3632, either alone or with other cancer treatments, for people with advanced blood cancers that have specific genetic changes (like KMT2Ar, NPM1m, or others that cause HOX over-expression). The goal is to see if it can help when standard treatments have stopped working.
Decatur, IllinoisAges 16 years+ - NCT05194397RecruitingPhase 2
Exercise plus NR supplement to boost fitness after stem-cell transplant
This trial tests whether a supervised exercise program, plus an NR supplement, can improve fitness in young people who have had an allogeneic (donor) stem-cell transplant for certain blood cancers or bone marrow conditions. It’s meant to help with energy and physical ability while monitoring safety.
Duarte, CaliforniaAges 10–30 - NCT06787144RecruitingPhase 1
Studying ELVN-001 for Japanese adults with CML
This trial tests a new drug called ELVN-001 for people with chronic myeloid leukemia (CML) who have not responded to or could not take at least two prior treatments. It's for Japanese patients, including those with a specific genetic change (T315I mutation). The goal is to see if ELVN-001 can help control the leukemia.
Akita, AkitaAges 18 years+ - NCT04838041RecruitingPhase 2
Testing stopping treatment after asciminib for CML relapse
This trial looks at whether people with chronic-phase CML who tried stopping a prior CML medicine and had to restart can later stop treatment again after a set period using asciminib. It checks whether you can stay in a deep remission (“free remission” without the usual CML tablets).
Detroit, MichiganAges 18 years+ - NCT06665412Recruiting
Radotinib Dose Reduction for Chronic Phase CML
This trial tests if lowering the dose of radotinib is safe and effective for adults newly diagnosed with a certain type of leukemia (chronic phase CML). It may help control the disease while reducing side effects.
Anyang-si, Gyeonnggi-doAges 19 years+ - NCT06629584RecruitingPhase 2
Asciminib for second-line chronic phase CML
This study tests a pill called asciminib for people with chronic phase CML whose first targeted therapy didn't work or caused side effects. The goal is to see if asciminib can better control the disease with fewer problems.
Houston, TexasAges 18 years+ - NCT07573111RecruitingPhase 1
QUAIL-100 for Children With Blood Cancers After Stem Cell Transplant
This study tests a new experimental treatment called QUAIL-100 in children and young adults who have had a stem cell transplant for a serious blood cancer. The treatment is designed to help the immune system fight remaining cancer cells.
Palo Alto, CaliforniaAges 1.5 years–39 years - NCT03326310RecruitingPhase 1
Selumetinib plus azacitidine for high-risk blood cancers
This Phase 1 trial tests whether selumetinib and azacitidine can help people with high-risk chronic blood cancers. You may qualify if your disease is higher risk and has either come back, not responded, or needs treatment because of low blood counts or other concerning features.
Chicago, IllinoisAges 18 years+ - NCT03459534RecruitingPhase 3
Radotinib for CML patients after prior TKI failure
This trial tests radotinib (a targeted pill) in people with chronic-phase Philadelphia chromosome–positive CML whose previous TKIs stopped working or could not be tolerated. It aims to improve control of the leukemia while checking safety.
BarnaulAges 18 years+ - NCT05367700RecruitingPhase 1
Test drug HS-10382 for chronic myeloid leukemia after prior treatment
This early-phase study tests HS-10382 in adults with chronic myeloid leukemia (CML) whose leukemia is resistant to or not tolerated of standard pills. It aims to see if the drug can control CML when earlier treatment hasn’t worked for you.
Wuhan, HubeiAges 18–74 - NCT06514534RecruitingPhase 2
Asciminib for CML with T315I mutation and ponatinib problems
This trial tests a new drug called asciminib for people with CML who have a specific genetic change (T315I) and cannot take or did not benefit from the drug ponatinib. The goal is to see if asciminib can help control the leukemia.
BordeauxAges 18–99 - NCT04920968RecruitingPhase 2
Obinutuzumab versus rituximab for newly diagnosed ALL
This Phase 2 study compares two antibody treatments—obinutuzumab and rituximab—for newly diagnosed acute lymphoblastic leukemia (ALL) that has the CD20 marker. It aims to see which treatment works better and is safe for people whose leukemia cells have CD20.
BialystokAges 18 years+ - NCT07072494RecruitingPhase 1/Phase 2
CD19 CAR-T cells as consolidation for B-cell ALL
This trial tests a single infusion of CD19 CAR-T cells as a consolidation treatment to keep leukemia in remission for patients who are not eligible for or decline a stem cell transplant. The goal is to see if this therapy can prevent relapse.
Guangzhou, GuangdongAges 14–80 - NCT07503730RecruitingPhase 3
Early use of realgar-indigo naturalis formula plus ATRA for APL patients
This trial tests whether giving a combination of two oral medicines—realgar-indigo naturalis formula (RIF) and all-trans retinoic acid (ATRA)—early in treatment can help people with acute promyelocytic leukemia (APL), a specific type of blood cancer. The goal is to see if this approach works better than current standard care.
Xi'an, ShaanxiAges 18–80 - NCT07246707RecruitingPhase 1
KSV01 injection for relapsed or refractory B-cell acute lymphoblastic leukemia
This trial tests an investigational drug called KSV01 for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or hasn't responded to standard treatments. It aims to see if the drug can help control the cancer.
HangzhouAges 18–80 - NCT04179929Recruiting
Study for adults with Ph-negative ALL
This trial looks at how to treat a type of leukemia called Ph-negative ALL in adults. It may help people by testing a treatment approach specifically for this leukemia subtype.
Badalona, BarcelonaAges 18–60 - NCT04227015RecruitingEarly Phase 1
Study of a CD19 CAR T-cell treatment for relapsed leukemia
This early-phase trial tests an injected “CAR T” cell therapy made to attack CD19-positive blood cancers that have come back or did not respond. If you qualify, the study checks whether the treatment can help control the cancer and is safe enough to study further.
Hangzhou, ZhejiangAges 3–70 - NCT04512716RecruitingEarly Phase 1
Radioimmunotherapy then CD19 CAR T for hard-to-treat blood cancers
This early-phase study tests a two-step treatment: first a targeted radioactive antibody (131-I apamistamab) and then CD19 CAR T-cell therapy. It is for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) or diffuse large B-cell lymphoma (DLBCL) that is not responding or has come back, aiming to shrink cancer using engineered immune cells.
Basking Ridge, New JerseyAges 18 years+ - NCT05887167RecruitingPhase 1
Test safety of making CAR T cells from your own blood
This Phase 1 study looks at whether it is safe and practical to collect your own stem cells and use them to support CAR T-cell therapy for certain blood cancers that have come back or did not respond. It aims to find the best way to combine these steps, which may help some people receive CAR T treatment.
Los Angeles, CaliforniaAges 18–85 - NCT06051409RecruitingPhase 3
Olverembatinib for newly diagnosed Ph+ ALL
This trial tests a new targeted drug, olverembatinib, in adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this drug can help control the leukemia with manageable side effects.
Birmingham, AlabamaAges 18 years+
Hear when a new Leukemia Acute Myeloid - AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia acute myeloid - aml?
- Yes. Clin2 currently lists 100 recruiting leukemia acute myeloid - aml studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia acute myeloid - aml trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia acute myeloid - aml trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.